PF-04449913
PF-04449913 is a pharmaceutical drug with 7 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 7 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
7 of 7 finished
0.0%
0 ended early
0
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
A Study Of PF-04449913 In Select Hematologic Malignancies
Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Clinical Trials (7)
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
A Study Of PF-04449913 In Select Hematologic Malignancies
Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma
A Study Of PF-04449913 Administered Alone In Select Solid Tumors
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7